Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax

Protara Therapeutics Inc

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Data: Novavax, which is in the final legs of completing the COVID-19 vaccine race, is moving on success in another arena.

Why Novavax, Inovio, and Protara Are Moving Today

The biotech said the decision was based on the wide availability of shots in the U.S., although the Phase 3 trial of the drug will go forward abroad.

Inovio Dives After Government Backs Out of Covid Vaccine Deal

Shares of Inovio Pharmaceuticals Inc. plunged 29.7% toward a 13-month low, enough to pace all premarket decliners Friday, after the company said the U.S. government has cut off funding for the Phase 3 trial of its COVID-19 vaccine candidate because vaccines are already broadly available. The company said it will continue with its work toward a Phase 3 trial, but is now planning a "predominantly ex-U.S." trial for its COVID-19 vaccine candidate, INO-4800.

Inovio stock plunges after U.S. government stops funding of Phase 3 trial of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's plans for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, will discontinue funding for the Phase 3 portion of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 part.

Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) fell by over 20% pre-market. This is why it happened.

INO Stock: Over 20% Decrease Pre-Market Explanation

PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800.

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

It's all about the ultimate coronavirus vaccine.

Here's the Dr. Fauci Statement That Could Mean Good News for Inovio

CureVac B.V

Immunic Inc

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) increased by over 15% during intraday trading. This is why it happened.

INO Stock: Over 15% Increase Intraday Explanation

PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern.

INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

Do Options Traders Know Something About Inovio (INO) Stock We Don't?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO). On March 9, 2020 Citron Research published a statement highlighting the Company's “ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours” and calling for an SEC investigation into the claims. That same day, the Com

INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO

It has to do with game-changing technology.

This 1 Element May Be Holding Inovio's Vaccine Back

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

Inovio Is Still Working On A Midstage Covid Vaccine Test — Is It A Buy?

We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14.

Down 40% From Recent Highs Can Inovio Pharmaceuticals Stock Rebound?

Inovio VGX-3100 HPV Data Adds To Conviction

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst.  The Inovio Analyst: Geoff Meacham initiated coverage of Inovio with a Neutral rating and $13 price target.

Inovio Has 'Bigger Value Drivers' Outside Of COVID-19 Vaccine Program: BofA Analyst

DraftKings

GlaxoSmithKline

Southwest Airlines

Netflix

Alexion Pharma

Burlington Stores

MongoDB

Snowflake

With the trading day about halfway over, the broad markets had pulled back slightly.

DraftKings, GlaxoSmithKline, Netflix, Southwest and More Tuesday Afternoon Analyst Calls

Vaxart

Let's look at what some of the smartest investors are saying.

Vaxart or Inovio: Which Is More Likely to Double Your Money?

Blink Charging

GameStop

SNDL Inc.

Although these stocks are popular with the Reddit community, they're bad news.

4 Heavily Short-Sold Stocks to Avoid Like the Plague

PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel.

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

The biotech could be a winner over the long run but faces some significant challenges.

What Are the Prospects for Inovio's COVID Vaccine?

There was one big wrinkle with the biotech's study.

Why Investors Didn't Like Inovio's Seemingly Positive Clinical Results

INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead The post Sell Inovio While You Still Can appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

Sell Inovio While You Still Can

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ten trading days, while it's down 14% over the last five trading days, but we believe the stock, after the.

News for Inovio Pharmaceuticals Stock (INO)